Healthcare Industry News: kidney disease
News Release - June 26, 2012
Spiracur Announces New SNaP Bridge Dressing for Plantar Surface Wound CareAdvanced Wound Care Product Designed to Improve Diabetic Foot Ulcer Treatment
SUNNYVALE, CA--(Healthcare Sales & Marketing Network)- Spiracur Inc., the developer of disposable, non-powered negative pressure wound therapy (NPWT) solutions, today announced the introduction of the SNaP® Wound Care System's Bridge Dressing for the plantar surface of the foot. The new dressing is designed to move pressure points off of the wound and deliver effective, continuous treatment. When partnered with an offloading device, such as a protective boot, it offers a complete solution to treat plantar surface diabetic foot ulcers (DFUs), one of the most incapacitating complications resulting from diabetes.
"Amputations as a result of non-healing or untreated DFUs are devastating for patients and extremely costly to our healthcare system, accounting for an estimated $116 billion in direct medical costs," said Leslie Oldenbrook, DPM, from the O'Connor Wound Care Center. "It is imperative that DFUs are treated immediately because the longer a wound remains unhealed, the greater the risk to the patient. The SNaP Bridge Dressing offers an advanced negative pressure therapy solution for treating plantar surface DFUs by removing any additional hard pressure points from the weight bearing surface and providing continuous, safe therapy," continued Dr. Oldenbrook.
According to the National Institute of Diabetes & Digestive & kidney diseases (NIDDK), 25.8 million, or 8.3 percent of the U.S. population has or will develop diabetes in their lifetime. Among them, 10-15 percent will develop a DFU at some point. If DFUs are not treated properly, there can be serious complications including amputation and/or death. In fact, untreated DFUs have a higher mortality rate than prostate cancer, breast cancer and Hodgkin's lymphoma.
"We are proud to offer patients and clinicians the SNaP Bridge Dressing, the latest offering in our expanding product portfolio for the successful treatment of chronic wounds," said Gary Restani, president and chief executive officer, Spiracur Inc. "Because treatment of DFUs can be difficult, it was essential that our team of engineers design and develop an effective solution to address this serious and increasingly common health problem. We are optimistic that our integrated approach to plantar surface wound care may help to reduce complications associated with diabetic foot ulcers and resulting amputations."
About Spiracur Inc.
Spiracur Inc., headquartered in Sunnyvale, Calif., is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System for the treatment of chronic and acute wounds, is the result of patient and clinician feedback that current negative pressure wound therapies were too cumbersome. The company's ciSNaP™ Closed Incision System with proprietary controlled tension relief is designed to improve healing of high-risk surgical incisions. Both devices have been cleared by the U.S. Food & Drug Administration (FDA) and have received CE Mark approval. For more information, please visit http://spiracur.com.
Spiracur, Spiracur logo, SNaP and Smart Negative Pressure are registered trademarks, and ciSNaP is a trademark of Spiracur Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.